AcuCort AB (publ) hereby announces that the company’s Annual Report for the financial year 2022 has been published in Swedish.
The Annual Report in Swedish, which is attached, can also be downloaded from the company’s website, the IR page.
The information was submitted for publication, through the agency of the contact person below, on April 14, 2023.
For further information please contact:
Jonas Jönmark, vd, AcuCort AB
Telefon: 070 365 5400
About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. All in all, it strengthens the company’s assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.